Back to results
US 7,547,781 B2Granted
Quinazoline based EGFR inhibitors containing a zinc binding moiety
AssigneeCuris, Inc.
InventorsChanggeng Qian, Xiong Cai, Stephen Gould
Life of this patent
Estimating the term…
Abstract
The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
Claims9
A compound represented by formula I:
- or a pharmaceutically acceptable salt, wherein
- X is O, S, CH2, or-CONH-;
- B is a C3 to C9 alkylene;
- R1 is selected from hydrogen, C1 to C4 alkoxy or substituted C1 to C4 alkoxy;
- R2 is each independently selected from halogen, C1 to C4 alkyl, C2 to C4 alkenyl, and C2 to C4 alkynyl;
- and
- n is 1,2 or 3.
4 more elements
Dependencies are inferred from the claim text.